Abstract
The health effects of air pollution have been subject to intense study in recent years. These effects have been found in short-term studies, which relate day-to-day variations in air pollution and health, and long-term studies, which have followed cohorts of exposed individuals over time. Epidemiological evidence has concurred with clinical and experimental evidence to correlate current levels of ambient air pollution, both indoors and outdoors, with respiratory effects. The association between ambient air pollution exposure and lung cancer risk indicates that long-term exposure to air pollution may cause lung cancer. In the 1950s evidence of an ongoing epidemic of lung cancer in the United States and Europe led researchers to examine the role of outdoor air pollution, which was considered by some to be a likely cause. This concern is based on the fact that known carcinogens continue to be released into outdoor air from industrial sources, power plants, and motor vehicles. The present article reviews the epidemiologic evidence for this association and discusses the limitations of current studies for estimating the lung cancer risk in the general population. It also identifies research needs and suggests possible approaches to addressing outstanding questions like the causality assessment, which can benefit from biomarker research.
Keywords: Air pollution, ambient air, epidemiology, motor vehicle, traffic, lung cancer, polycyclic aromatic hydrocarbons, biomarker, review.
Current Respiratory Medicine Reviews
Title:Air Pollution and Lung Cancer
Volume: 8 Issue: 6
Author(s): Sagrario Mayoralas-Alises and Salvador Diaz-Lobato
Affiliation:
Keywords: Air pollution, ambient air, epidemiology, motor vehicle, traffic, lung cancer, polycyclic aromatic hydrocarbons, biomarker, review.
Abstract: The health effects of air pollution have been subject to intense study in recent years. These effects have been found in short-term studies, which relate day-to-day variations in air pollution and health, and long-term studies, which have followed cohorts of exposed individuals over time. Epidemiological evidence has concurred with clinical and experimental evidence to correlate current levels of ambient air pollution, both indoors and outdoors, with respiratory effects. The association between ambient air pollution exposure and lung cancer risk indicates that long-term exposure to air pollution may cause lung cancer. In the 1950s evidence of an ongoing epidemic of lung cancer in the United States and Europe led researchers to examine the role of outdoor air pollution, which was considered by some to be a likely cause. This concern is based on the fact that known carcinogens continue to be released into outdoor air from industrial sources, power plants, and motor vehicles. The present article reviews the epidemiologic evidence for this association and discusses the limitations of current studies for estimating the lung cancer risk in the general population. It also identifies research needs and suggests possible approaches to addressing outstanding questions like the causality assessment, which can benefit from biomarker research.
Export Options
About this article
Cite this article as:
Mayoralas-Alises Sagrario and Diaz-Lobato Salvador, Air Pollution and Lung Cancer, Current Respiratory Medicine Reviews 2012; 8 (6) . https://dx.doi.org/10.2174/1573398X11208060004
DOI https://dx.doi.org/10.2174/1573398X11208060004 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vascular Disrupting Agents (VDA) in Oncology: Advancing Towards New Therapeutic Paradigms in the Clinic
Current Drug Targets IMGT Colliers de Perles: Standardized Sequence-Structure Representations of the IgSF and MhcSF Superfamily Domains
Current Bioinformatics From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
Current Neuropharmacology Identification of Novel Drug Targets for Angiostatic Cancer Therapy; It Takes Two to Tango
Current Pharmaceutical Design A New Era of Immunotherapy in Prostate Cancer
Current Molecular Pharmacology IMPMD: An Integrated Method for Predicting Potential Associations Between miRNAs and Diseases
Current Genomics Synthesis of Biologically Potent Novel 5-(2-bromopyridin-3-yl-amino)-2- alkyl/aryl-isoindoline-1,3-dione Analogs Via Buchwald-Hartwig C-N Coupling Reaction
Letters in Organic Chemistry Novel Synthetic Lethality Approaches for Drug Combinations and Early Drug Development
Current Cancer Drug Targets Epigenetic Modifications Due to Heavy Metals Exposure in Children Living in Polluted Areas
Current Genomics Involvement of Membrane Channels in Autoimmune Disorders
Current Pharmaceutical Design High-Dose Linoleic Acid Activated JAK2-STAT3 Signaling Pathway Involved in Cytokine Production and Lipogenesis in Pancreatic Exocrine Cells
Current Molecular Medicine A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor
Current Cancer Drug Targets Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs)
Current Cancer Drug Targets Discovery of Hybrid Purine-quinoline Molecules and Their Cytotoxic Evaluation
Letters in Drug Design & Discovery ADAM Metalloproteinases as Potential Drug Targets
Current Medicinal Chemistry Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Medicinal Chemistry Targeting Histone Deacetylases for the Treatment of Immune, Endocrine & Metabolic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-Proliferative, Anti-Inflammatory, Anti-Ulcerogenic and Wound Healing Properties of Chitosan
Current Bioactive Compounds Preface
Current Nanomedicine Overview of Ribonucleotide Reductase Inhibitors: An Appealing Target in Anti-Tumour Therapy
Current Medicinal Chemistry